neuroendocrine neoplasms

You have access
An Investigation of Lesion Detection Accuracy for Artificial Intelligence–Based Denoising of Low-Dose ⁶⁴Cu-DOTATATE PET Imaging in Patients with Neuroendocrine Neoplasms
Mathias Loft, Claes N. Ladefoged, Camilla B. Johnbeck, Esben A. Carlsen, Peter Oturai, Seppo W. Langer, Ulrich Knigge, Flemming L. Andersen and Andreas Kjaer

Journal of Nuclear Medicine June 1, 2023, 64 (6) 951-959; DOI: https://doi.org/10.2967/jnumed.122.264826
You have access
Prospective Phase II Trial of [⁶⁸Ga]Ga-NODAGA-E[c(RGDyK)]₂ PET/CT Imaging of Integrin α_vβ₃ for Prognostication in Patients with Neuroendocrine Neoplasms
Esben Andreas Carlsen, Mathias Loft, Annika Loft, Dorota Czyzewska, Mikkel Andreassen, Seppo W. Langer, Ulrich Knigge and Andreas Kjaer

Journal of Nuclear Medicine February 1, 2023, 64 (2) 252-259; DOI: https://doi.org/10.2967/jnumed.122.264383
You have access
Prospective Phase II Trial of Prognostication by ⁶⁸Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy
Esben Andreas Carlsen, Mathias Loft, Annika Loft, Anne Kiil Berthelsen, Seppo W. Langer, Ulrich Knigge and Andreas Kjaer

Journal of Nuclear Medicine September 1, 2022, 63 (9) 1371-1377; DOI: https://doi.org/10.2967/jnumed.121.263177
You have access
Semiautomatic Tumor Delineation for Evaluation of ⁶⁴Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume
Esben Andreas Carlsen, Camilla Bardram Johnbeck, Mathias Loft, Andreas Pfeifer, Peter Oturai, Seppo W. Langer, Ulrich Knigge, Claes Nøhr Ladefoged and Andreas Kjaer

Journal of Nuclear Medicine November 1, 2021, 62 (11) 1564-1570; DOI: https://doi.org/10.2967/jnumed.120.258392
You have access
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski and Erik Mittra

Journal of Nuclear Medicine October 1, 2021, 62 (10) 1323-1329; DOI: https://doi.org/10.2967/jnumed.120.251512
You have access
⁶⁴Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection
Mathias Loft, Esben A. Carlsen, Camilla B. Johnbeck, Helle H. Johannesen, Tina Binderup, Andreas Pfeifer, Jann Mortensen, Peter Oturai, Annika Loft, Anne K. Berthelsen, Seppo W. Langer, Ulrich Knigge and Andreas Kjaer

Journal of Nuclear Medicine January 1, 2021, 62 (1) 73-80; DOI: https://doi.org/10.2967/jnumed.120.244509
You have access
Prognostic Value of ¹⁸F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy
Jingjing Zhang, Qingxing Liu, Aviral Singh, Christiane Schuchardt, Harshad R. Kulkarni and Richard P. Baum

Journal of Nuclear Medicine November 1, 2020, 61 (11) 1560-1569; DOI: https://doi.org/10.2967/jnumed.119.241414
You have access
Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients
Jingjing Zhang, Harshad R. Kulkarni, Aviral Singh, Karin Niepsch, Dirk Müller and Richard P. Baum

Journal of Nuclear Medicine March 1, 2019, 60 (3) 377-385; DOI: https://doi.org/10.2967/jnumed.118.215848
You have access
Prognostic Value of ¹⁸F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with ¹⁸F-FDG PET and Ki-67 in 100 Patients
Camilla B. Johnbeck, Ulrich Knigge, Seppo W. Langer, Annika Loft, Anne Kiil Berthelsen, Birgitte Federspiel, Tina Binderup and Andreas Kjaer

Journal of Nuclear Medicine December 1, 2016, 57 (12) 1851-1857; DOI: https://doi.org/10.2967/jnumed.116.174714

Main menu

User menu

Search

neuroendocrine neoplasms